(90)y-Ibritumumab Tiuxetan (Zevalin (R))-BEAM/C with Autologous Stem Cell Support as Frontline Therapy for Advanced Mantle Cell Lymphoma.- Preliminary Results From the Third Nordic MCL Phase II Study (MCL3)

Arne Kolstad; Anna Laurell; Niels S. Andersen; Erkki Elonen; Riikka Raty; Lone Bredo Pedersen; Annika Loft; Trond Velde Bogsrud; Marie Nordstrom; Dorte Gillstrom; Per Boye Hansen; Hans Bentzen; Unn-Merete Fagerli; Peter Meyer; Herman Nilsson-Ehle; Mats Jerkeman; Anne Kristine Lehmann; Grete F. Lauritzsen; Christer Sundstrom; Jan Delabie; Marja-Liisa Karjalainen-Lindsberg; Elisabeth Ralfkiaer; Mats Ehinger; Christian H. Geisler

(90)y-Ibritumumab Tiuxetan (Zevalin (R))-BEAM/C with Autologous Stem Cell Support as Frontline Therapy for Advanced Mantle Cell Lymphoma.- Preliminary Results From the Third Nordic MCL Phase II Study (MCL3)

Arne Kolstad, Anna Laurell, Niels S. Andersen, Erkki Elonen, Riikka Raty, Lone Bredo Pedersen, Annika Loft, Trond Velde Bogsrud, Marie Nordstrom, Dorte Gillstrom, Per Boye Hansen, Hans Bentzen, Unn-Merete Fagerli, Peter Meyer, Herman Nilsson-Ehle, Mats Jerkeman, Anne Kristine Lehmann, Grete F. Lauritzsen, Christer Sundstrom, Jan DelabieMarja-Liisa Karjalainen-Lindsberg, Elisabeth Ralfkiaer, Mats Ehinger, Christian H. Geisler

Forskningsoutput: Tidskriftsbidrag › Publicerat konferensabstract › Peer review

Originalspråk	engelska
Sidor (från-till)	384-384
Tidskrift	Blood
Volym	114
Nummer	22
Status	Published - 2009
Evenemang	51st Annual Meeting of the American-Society-of-Hematology - New Orleans, LA Varaktighet: 2009 dec. 5 → 2009 dec. 8

Bibliografisk information

The information about affiliations in this record was updated in December 2015.
The record was previously connected to the following departments: Oncology, MV (013035000), Pathology, (Lund) (013030000)

Ämnesklassifikation (UKÄ)

Hematologi

Citera det här

Kolstad, A., Laurell, A., Andersen, N. S., Elonen, E., Raty, R., Pedersen, L. B., Loft, A., Bogsrud, T. V., Nordstrom, M., Gillstrom, D., Hansen, P. B., Bentzen, H., Fagerli, U-M., Meyer, P., Nilsson-Ehle, H., Jerkeman, M., Lehmann, A. K., Lauritzsen, G. F., Sundstrom, C., ... Geisler, C. H. (2009). (90)y-Ibritumumab Tiuxetan (Zevalin (R))-BEAM/C with Autologous Stem Cell Support as Frontline Therapy for Advanced Mantle Cell Lymphoma.- Preliminary Results From the Third Nordic MCL Phase II Study (MCL3). Blood, 114(22), 384-384.

@article{31dcaf4896ac428aac077e713431f93f,

title = "(90)y-Ibritumumab Tiuxetan (Zevalin (R))-BEAM/C with Autologous Stem Cell Support as Frontline Therapy for Advanced Mantle Cell Lymphoma.- Preliminary Results From the Third Nordic MCL Phase II Study (MCL3)",

author = "Arne Kolstad and Anna Laurell and Andersen, {Niels S.} and Erkki Elonen and Riikka Raty and Pedersen, {Lone Bredo} and Annika Loft and Bogsrud, {Trond Velde} and Marie Nordstrom and Dorte Gillstrom and Hansen, {Per Boye} and Hans Bentzen and Unn-Merete Fagerli and Peter Meyer and Herman Nilsson-Ehle and Mats Jerkeman and Lehmann, {Anne Kristine} and Lauritzsen, {Grete F.} and Christer Sundstrom and Jan Delabie and Marja-Liisa Karjalainen-Lindsberg and Elisabeth Ralfkiaer and Mats Ehinger and Geisler, {Christian H.}",

note = "The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Oncology, MV (013035000), Pathology, (Lund) (013030000); 51st Annual Meeting of the American-Society-of-Hematology ; Conference date: 05-12-2009 Through 08-12-2009",

year = "2009",

language = "English",

volume = "114",

pages = "384--384",

journal = "Blood",

issn = "1528-0020",

publisher = "American Society of Hematology",

number = "22",

}

Kolstad, A, Laurell, A, Andersen, NS, Elonen, E, Raty, R, Pedersen, LB, Loft, A, Bogsrud, TV, Nordstrom, M, Gillstrom, D, Hansen, PB, Bentzen, H, Fagerli, U-M, Meyer, P, Nilsson-Ehle, H, Jerkeman, M, Lehmann, AK, Lauritzsen, GF, Sundstrom, C, Delabie, J, Karjalainen-Lindsberg, M-L, Ralfkiaer, E, Ehinger, M & Geisler, CH 2009, '(90)y-Ibritumumab Tiuxetan (Zevalin (R))-BEAM/C with Autologous Stem Cell Support as Frontline Therapy for Advanced Mantle Cell Lymphoma.- Preliminary Results From the Third Nordic MCL Phase II Study (MCL3)', Blood, vol. 114, nr. 22, s. 384-384.

(90)y-Ibritumumab Tiuxetan (Zevalin (R))-BEAM/C with Autologous Stem Cell Support as Frontline Therapy for Advanced Mantle Cell Lymphoma.- Preliminary Results From the Third Nordic MCL Phase II Study (MCL3). / Kolstad, Arne; Laurell, Anna; Andersen, Niels S. et al.

I: Blood, Vol. 114, Nr. 22, 2009, s. 384-384.

Forskningsoutput: Tidskriftsbidrag › Publicerat konferensabstract › Peer review

TY - JOUR

T1 - (90)y-Ibritumumab Tiuxetan (Zevalin (R))-BEAM/C with Autologous Stem Cell Support as Frontline Therapy for Advanced Mantle Cell Lymphoma.- Preliminary Results From the Third Nordic MCL Phase II Study (MCL3)

AU - Kolstad, Arne

AU - Laurell, Anna

AU - Andersen, Niels S.

AU - Elonen, Erkki

AU - Raty, Riikka

AU - Pedersen, Lone Bredo

AU - Loft, Annika

AU - Bogsrud, Trond Velde

AU - Nordstrom, Marie

AU - Gillstrom, Dorte

AU - Hansen, Per Boye

AU - Bentzen, Hans

AU - Fagerli, Unn-Merete

AU - Meyer, Peter

AU - Nilsson-Ehle, Herman

AU - Jerkeman, Mats

AU - Lehmann, Anne Kristine

AU - Lauritzsen, Grete F.

AU - Sundstrom, Christer

AU - Delabie, Jan

AU - Karjalainen-Lindsberg, Marja-Liisa

AU - Ralfkiaer, Elisabeth

AU - Ehinger, Mats

AU - Geisler, Christian H.

N1 - The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Oncology, MV (013035000), Pathology, (Lund) (013030000)

PY - 2009

Y1 - 2009

M3 - Published meeting abstract

SN - 1528-0020

VL - 114

SP - 384

EP - 384

JO - Blood

JF - Blood

IS - 22

T2 - 51st Annual Meeting of the American-Society-of-Hematology

Y2 - 5 December 2009 through 8 December 2009

ER -